Acute Liver Failure

• Massive hepatocyte necrosis and apoptosis: The inciting cause (whether toxin, virus, or immune-mediated) triggers rapid hepatocyte death through multiple pathways. In acetaminophen-induced ALF, N-acetyl-p-benzoquinone imine (NAPQI), a highly reactive metabolite of CYP2E1-catalyzed acetaminophen metabolism, depletes hepatic glutathione stores and forms irreversible protein adducts, causing mitochondrial dysfunction and caspase-mediated apoptosis. Viral hepatitis (HAV, HBV, HEV) induces direct cytotoxic injury via viral replication and triggers immune-mediated hepatocellular destruction through CD8+ T-cell responses. Autoimmune hepatitis involves aberrant Th17 and B-cell responses targeting hepatocyte antigens. Regardless of etiology, loss of >80% of functional hepatic mass occurs, exceeding the liver's remarkable regenerative capacity during this critical window.

• Profound coagulopathy and synthesis failure: The liver synthesizes virtually all clotting factors except von Willebrand factor (vWF). Rapid loss of hepatocytes results in decreased production of factors I, II, V, VII, IX, and X, with factor V being particularly sensitive to hepatocellular injury due to its short half-life (24 hours). This produces a characteristic coagulopathy with elevation of INR/PT while PTT may be disproportionately prolonged. Critically, platelet count is often normal or only mildly reduced initially, distinguishing ALF coagulopathy from DIC. Factor V levels <20% of normal correlate with poor prognosis. Additionally, decreased synthesis of inhibitors (protein C, protein S, antithrombin) paradoxically increases thrombotic risk despite bleeding manifestations—ALF generates a prothrombotic microenvironment despite macroscopic bleeding, with elevated D-dimer and thrombin-antithrombin complexes indicating ongoing thrombin generation.

• Cerebral edema and hepatic encephalopathy pathophysiology: The development of encephalopathy is the defining feature distinguishing ALF from acute hepatitis. Multiple mechanisms contribute. The "ammonia hypothesis" suggests that impaired hepatic ammonia clearance, combined with portosystemic shunting, permits ammonia and other neurotropic substances to directly affect the brain. Ammonia is metabolized primarily by the liver via the urea cycle and glutamine synthetase pathway; loss of hepatic mass results in hyperammonemia (often >200 μmol/L). Elevated ammonia crosses the blood-brain barrier via LNAA (large neutral amino acid) transporters, where it is metabolized in astrocytes by glutamine synthetase to glutamine, leading to osmotic stress, astrocyte swelling, and cytotoxic edema. The "manganese hypothesis" posits that manganese accumulates in ALF due to decreased hepatic excretion, depositing in basal ganglia and disturbing dopaminergic neurotransmission. The "false neurotransmitter hypothesis" implicates elevated aromatic amino acids (phenylalanine, tyrosine) relative to branched-chain amino acids (BCAA ratio inversion), increasing formation of octopamine and other false neurotransmitters. Pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) are markedly elevated and directly contribute to cerebral edema through disruption of the blood-brain barrier, increased vascular permeability, and astrocytic activation. Microglia undergo activation, releasing further cytokines and reactive oxygen species. Brain swelling is both cytotoxic (intracellular) and vasogenic (extracellular), and if unchecked, leads to transtentorial herniation and brain stem death.

• Systemic inflammatory response and multi-organ dysfunction: ALF triggers a severe systemic inflammatory cascade—a "cytokine storm"—with massive release of TNF-α, IL-6, IL-10, and chemokines, creating a pro-inflammatory microenvironment that paradoxically coexists with immunosuppression. This inflammation drives vasodilation and capillary leak, resulting in the hepatorenal syndrome pathophysiology: splanchnic vasodilation activates neurohormonal reflexes (RAAS, SNS, non-osmotic ADH release), causing renal vasoconstriction and hepatorenal syndrome (HRS). Additionally, massive release of tissue factor (TF) from damaged hepatocytes and infiltrating macrophages activates the extrinsic coagulation pathway, yet simultaneously, consumption and dysfunction of platelets, widespread fibrinolysis, and decreased factor synthesis create a paradoxical coagulopathy. Acute kidney injury (AKI) develops in 60–80% of ALF cases through multiple mechanisms: HRS Type 1 (functional renal failure), acute tubular necrosis from hypoperfusion, and direct toxic effects. Metabolic acidosis develops from lactate accumulation due to impaired hepatic clearance and anaerobic metabolism. Severe hypoglycemia results from loss of gluconeogenesis and glycogenolysis, compounded by depletion of glycogen stores and hyperinsulinism. Lactic acidosis reflects profound circulatory collapse, with lactate levels >4 mmol/L indicating extremely poor prognosis.

• Impaired host defense and infection risk: The liver plays a central role in innate immunity through production of complement, fibronectin, lysozyme, and lactoferrin, and hepatic clearance of portal blood-borne bacteria via Kupffer cells. In ALF, loss of these functions combined with neutrophil dysfunction, reduced opsonization, and impaired monocyte activation results in severe immunosuppression despite elevated inflammatory markers. Consequently, bacterial and fungal infections occur in 80% of ALF cases, often without localizing signs, and directly contribute to mortality through sepsis and multi-organ failure.

• Acetaminophen (paracetamol) toxicity: Accounts for 45–50% of ALF cases in the United States and is the most common single cause of ALF in Western countries. Toxicity follows either acute massive overdose (typically >15 g in adults) or chronic therapeutic misuse (cumulative overdose) in susceptible individuals. CYP2E1-mediated metabolism produces NAPQI, which depletes hepatic glutathione (GSH) stores, leading to mitochondrial damage and hepatocyte necrosis. Risk factors for severe toxicity include chronic alcohol use (induces CYP2E1 and depletes GSH), malnutrition, fasting, and dehydration (reduce GSH synthesis), concurrent use of other hepatotoxins, and genetic polymorphisms in drug-metabolizing enzymes. Critically, ingestion history may be unreliable; many acetaminophen-ALF cases result from unintentional overdose via combination products or use by patients with substance use disorder or psychiatric illness seeking self-harm.

• Viral hepatitis: Hepatitis A (HAV), B (HBV), C (HCV), D (HDV), and E (HEV) are all capable of causing ALF. HAV causes ALF in approximately 0.1–0.3% of infected individuals overall, but rates approach 1–3% in those >50 years old and in patients with pre-existing chronic HBV infection. HBV accounts for 10–25% of ALF cases in endemic regions and in some developed countries, particularly in patients with high viral loads and severe immune activation; HBeAg seroconversion and emergence of precore mutants are associated risk factors. HEV, endemic in developing countries and increasingly recognized in developed nations, causes ALF in 0.5–3% of infected individuals, with dramatically elevated rates (15–25%) in pregnant women, particularly in the third trimester—a classic board-testable association. HDV (hepatitis D) infection requires concurrent HBV and dramatically increases the risk of ALF. HCV rarely causes fulminant hepatic failure. Seronegative hepatitis (no identifiable etiology despite clinical evidence of viral hepatitis) accounts for 5–10% of cases and may represent unrecognized viruses or unusual pathogens.

• Autoimmune hepatitis: Accounts for 5–15% of ALF cases, particularly in younger patients and females. Type 1 autoimmune hepatitis (associated with anti-smooth muscle and anti-nuclear antibodies) is more common globally; Type 2 (anti-LKM antibodies) occurs predominantly in Europe. Disease develops when CD8+ T-cell responses breach tolerance to hepatocyte autoantigens, resulting in severe hepatitis and potentially ALF. Patients often lack serologic markers or have mild serologies at presentation, creating diagnostic difficulty.

• Drug-induced liver injury (DILI): Beyond acetaminophen, numerous drugs are capable of causing ALF. Isoniazid is the most common anti-tuberculosis drug causing severe hepatotoxicity (idiosyncratic reaction); rifampin and pyrazinamide contribute additional risk in combination regimens. Statins (particularly atorvastatin and simvastatin) cause ALF rarely but measurably. Antibiotics including amoxicillin-clavulanic acid (commonly associated with cholestatic hepatitis progressing to ALF), flucloxacillin, trimethoprim-sulfamethoxazole, and fluoroquinolones carry risk. Anticonvulsants (phenytoin, phenobarbital, carbamazepine) via metabolite-induced hypersensitivity. NSAIDs, antifungals (especially azoles), antiretrovirals (NRTIs), herbal supplements (kava, green tea extract, usnic acid), and anesthetic agents (halothane) are documented causes. DILI typically shows idiosyncratic hepatotoxicity with unpredictable latency (days to months) and higher individual susceptibility based on genetic polymorphisms in drug-metabolizing enzymes (CYP2C9, NAT2, HLA-B*5701, etc.).

• Pregnancy-related ALF: Acute fatty liver of pregnancy (AFLP) and HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) are unique obstetric emergencies occurring in the third trimester or immediately postpartum. AFLP carries ALF progression in 18–50% of cases and represents a microangiopathic hemolytic anemia with hepatic involvement driven by placental mitochondrial dysfunction and fetal metabolic gene mutations (notably LCHAD deficiency in the fetus). HELLP is considered a severe form of preeclampsia with hepatic consequences. Both mandate emergent delivery as the sole definitive treatment.

• Hepatic ischemia and shock: Severe hypotension from any cause (cardiogenic shock, sepsis, massive hemorrhage, anesthesia-related hypotension) can produce ischemic hepatitis (also called acute liver necrosis from shock). While often less fulminant than viral or toxic causes, ischemic hepatitis can progress to ALF if the insult is severe or prolonged.

• Herpes simplex virus (HSV) hepatitis: Particularly HSV-1 causes fulminant hepatitis in immunocompromised patients (transplant recipients, severe immunosuppression), pregnant women, and rarely immunocompetent hosts. Diagnosis is often delayed because clinical presentation mimics other causes and HSV hepatitis may lack classic vesicular lesions; PCR of blood/CSF and liver biopsy showing intranuclear inclusions and hepatocytic necrosis without significant inflammation establish diagnosis. Mortality exceeds 80% without treatment.

• Other infections: Cytomegalovirus (CMV) in immunocompromised hosts, Epstein-Barr virus (EBV) in patients with X-linked lymphoproliferative syndrome, and rarely acute tuberculosis can cause ALF. Sepsis from bacterial or fungal infections may precipitate ALF in vulnerable patients.

• Metabolic and genetic disorders: Wilson's disease classically presents as ALF in young adults (typically ages 5–30 years) with hemolytic anemia, neuropsychiatric symptoms, Kayser-Fleischer rings, and ceruloplasmin <20 mg/dL; this is a critical diagnosis not to miss because copper chelation therapy can be lifesaving. Mitochondrial depletion syndromes (nucleoside reverse-transcriptase inhibitors causing ALF), LCHAD deficiency in neonates, and other inborn errors of metabolism present in infancy or early childhood.

• Malignancy-related: Massive hepatic infiltration by lymphoma, leukemia, or metastatic cancer can cause ALF. Budd-Chiari syndrome from hepatic vein thrombosis (associated with myeloproliferative neoplasms, hypercoagulable states, malignancy) causes acute hepatic congestion and can rapidly progress to ALF.

• Constitutional prodrome and hepatitis symptoms: Most patients present with nonspecific prodromal symptoms lasting days to weeks: malaise, fatigue, myalgias, abdominal discomfort, nausea, and anorexia. As hepatic dysfunction accelerates, jaundice develops (bilirubin >3 mg/dL typically), manifesting as yellowing of sclera and skin. Right upper quadrant pain from hepatic capsular distension occurs. Pruritus results from bile salt accumulation. Patients may report dark urine (conjugated hyperbilirubinemia) and pale stools (decreased bile flow). Gastrointestinal symptoms dominate: persistent nausea, vomiting, and anorexia contribute to volume depletion and electrolyte abnormalities.

• Encephalopathy (the defining feature): Hepatic encephalopathy (HE) is the cardinal sign defining ALF from acute hepatitis and reflects severe cerebral dysfunction from hyperammonemia, false neurotransmitters, and pro-inflammatory mediators crossing the damaged blood-brain barrier. Encephalopathy develops in a prodromal stage of personality changes, sleep disturbance, and subtle cognitive dysfunction (particularly impaired concentration and executive function). Progression follows the West Haven criteria: Grade 1 (altered sleep, subtle personality change, impaired concentration); Grade 2 (lethargy, inappropriate behavior, disorientation to time); Grade 3 (somnolence yet arousable, gross disorientation, bizarre behavior); Grade 4 (coma). The rapidity of encephalopathy progression—hours to days in hyperacute ALF—reflects the severity of underlying hepatic necrosis and indicates worse prognosis but paradoxically better transplant survival (more hepatic regeneration potential). Asterixis (flapping tremor best elicited with wrist extension) is a classic sign but not pathognomonic. Papilledema may be visible. Fetor hepaticus (musty breath odor) reflects volatile mercaptan production.

• Coagulopathy and bleeding manifestations: **

• Initial laboratory panel: PT/INR is the single most important test because factor VII has the shortest half-life and falls first; it is both diagnostic and prognostic. Obtain simultaneously CBC, complete metabolic panel with creatinine, aminotransferases, bilirubin, alkaline phosphatase, albumin, lactate, arterial blood gas, glucose, and arterial ammonia.
• Pattern recognition on the chemistries: Aminotransferases in the thousands with a comparatively modest bilirubin suggests acetaminophen or ischemic injury; a very high bilirubin with only moderate transaminase elevation suggests a subacute or Wilson-type course. A low alkaline phosphatase, alkaline phosphatase-to-total-bilirubin ratio <4, and AST:ALT >2.2 with Coombs-negative hemolysis point to fulminant Wilson disease.
• Etiologic workup (send on every patient): acetaminophen level (and acetaminophen–protein adducts if available), viral serologies (anti-HAV IgM, HBsAg, anti-HBc IgM, anti-HEV, HSV PCR), autoimmune markers (ANA, ASMA, anti-LKM, IgG), ceruloplasmin and urinary copper, pregnancy test, toxicology screen, and Doppler ultrasound of the hepatic veins to exclude Budd–Chiari.
• Rumack–Matthew nomogram: applies only to a single acute acetaminophen ingestion with a known time, using a level drawn at ≥4 hours; it does not apply to staggered or chronic supratherapeutic ingestion, where N-acetylcysteine is given regardless.
• Ammonia: arterial ammonia correlates with cerebral edema risk — sustained markedly elevated levels (roughly above 150–200 μmol/L) predict intracranial hypertension and herniation.
• Imaging and biopsy: non-contrast head CT excludes hemorrhage but is insensitive for early edema. Transjugular liver biopsy is reserved for suspected malignant infiltration, autoimmune hepatitis, or HSV when the diagnosis changes management.

Immediate stabilization

• Transfer to a transplant center and ICU: AASLD guidance states that transfer should occur at the first sign of encephalopathy or coagulopathy, before the patient is too unstable to move — this is the single most impactful early decision.
• Airway: intubate for grade III–IV encephalopathy to protect against aspiration and control PaCO2; propofol is the preferred sedative because it is short-acting and lowers cerebral metabolic rate.
• Glucose and electrolytes: continuous dextrose infusion for the near-universal hypoglycemia from failed gluconeogenesis; correct hypophosphatemia and hypokalemia.

Cause-directed therapy

• N-acetylcysteine (IV): replenishes glutathione and detoxifies NAPQI. Give empirically for any suspected acetaminophen ingestion without waiting for levels; AASLD also supports NAC in *non*-acetaminophen ALF with grade I–II encephalopathy, where it improved transplant-free survival.
• Antivirals: nucleos(t)ide analogue (entecavir or tenofovir) for HBV-related ALF; IV acyclovir for suspected HSV hepatitis, started empirically because mortality is prohibitive if treatment is delayed.
• Other etiologies: penicillin G ± silibinin for Amanita phalloides; corticosteroids for autoimmune hepatitis (with low threshold to abandon if no response); chelation with albumin dialysis as a bridge in Wilson disease; emergent delivery is definitive for acute fatty liver of pregnancy and HELLP (ACOG).

Neuroprotection and escalation

• Intracranial hypertension: head of bed at 30°, minimal stimulation, hyperosmolar therapy with mannitol or hypertonic saline (target hypernatremia), and brief hyperventilation only as a bridge. Continuous — not intermittent — renal replacement therapy is preferred for AKI and ammonia clearance because it avoids osmolar swings.
• Infection: surveillance cultures with a low threshold for empiric broad-spectrum antibacterials and antifungals; routine prophylaxis is not mandated.
• High-volume plasma exchange is an adjunct at specialized centers.

Avoid

• Prophylactic FFP — it obscures the INR, the key prognostic and listing variable; transfuse only for bleeding or procedures.
• Nephrotoxins, hypotonic fluids, benzodiazepines, NSAIDs, and further acetaminophen. Lactulose has limited utility and may cause bowel distension complicating transplant.

Neurologic (highest early mortality)

• Cerebral edema and intracranial hypertension — emergency. Astrocyte glutamine accumulation produces cytotoxic swelling; risk rises with grade III–IV encephalopathy, hyperacute presentation, and markedly elevated arterial ammonia. Signals: systolic hypertension with bradycardia (Cushing reflex), pupillary asymmetry or loss of reactivity, decerebrate posturing, and abrupt loss of the sleep–wake pattern. Uncal herniation is the leading neurologic cause of death.
• Seizures: often nonconvulsive; unexplained failure to awaken after sedation is withdrawn should prompt EEG.

Metabolic and circulatory

• Hypoglycemia — emergency. Loss of gluconeogenesis and glycogen stores; may masquerade as worsening encephalopathy, so check a fingerstick before escalating neuro-workup.
• Lactic acidosis and vasoplegic shock: impaired hepatic lactate clearance plus cytokine-driven vasodilation; a rising lactate despite volume resuscitation is an ominous prognostic sign.
• Acute kidney injury / hepatorenal physiology: splanchnic vasodilation with renal vasoconstriction, superimposed ATN, and direct acetaminophen tubular toxicity; rising creatinine also worsens King's College scoring.

Infectious and hemostatic

• Bacterial and fungal sepsis: Kupffer cell failure, defective opsonization, and neutrophil dysfunction. Classically presents without fever or leukocytosis — a sudden deepening of encephalopathy or new hemodynamic instability may be the only clue, and infection can disqualify a patient from transplant.
• Bleeding: usually mucosal or GI from stress ulceration rather than spontaneous; give acid suppression prophylaxis. Note that despite the high INR, patients are in rebalanced hemostasis and can also clot.

Treatment-related

• N-acetylcysteine: anaphylactoid reactions (flushing, bronchospasm) during the loading infusion — histamine-mediated, managed by slowing the rate, not by abandoning the drug.
• Mannitol: hyperosmolality, volume overload, and worsening AKI; hypertonic saline causes hypernatremia and central pontine risk if reversed rapidly.
• Excessive hyperventilation: cerebral vasoconstriction and ischemia.
• Transfusion: volume overload and TRALI; intracranial pressure monitor placement carries hemorrhage risk in coagulopathy.
• Post-transplant: lifelong immunosuppression, opportunistic infection, and hepatic artery thrombosis.

• The definition is the answer to many stems: encephalopathy + INR ≥1.5 + no chronic liver disease + <26 weeks. Without encephalopathy it is severe acute hepatitis, not ALF.
• Single best next step in suspected acetaminophen ALF is IV N-acetylcysteine, given empirically before the level returns. Do not withhold NAC because presentation is late or the ingestion was staggered — the Rumack–Matthew nomogram applies only to a single acute ingestion timed ≥4 hours out.
• The other "best next step" examiners love: contact/transfer to a liver transplant center at the first sign of encephalopathy. Waiting for King's College criteria to be met before referring is the trap.
• Do not give prophylactic FFP to "fix" the INR. The INR is the prognostic clock and the transplant listing variable; correcting it blinds you. Transfuse only for active bleeding or before an invasive procedure.
• Fulminant Wilson disease buzzwords: young patient, Coombs-negative hemolytic anemia, low alkaline phosphatase, alkaline phosphatase-to-bilirubin ratio <4, AST:ALT >2.2, Kayser–Fleischer rings, low ceruloplasmin. Transplant is essentially always required — chelation alone will not rescue fulminant presentations.
• The association most tested: hepatitis E in the third trimester of pregnancy, with strikingly high mortality. Hepatitis C essentially does not cause ALF.
• Encephalopathy that is not encephalopathy: check a fingerstick glucose first. Hypoglycemia from failed gluconeogenesis is reversible in seconds and is the classic missed cause of obtundation.
• Common distractors: lactulose is the answer for cirrhotic hepatic encephalopathy, not for ALF cerebral edema — hyperosmolar therapy is. Benzodiazepines for agitation will deepen encephalopathy. A new fever is often absent in ALF sepsis, so its absence does not exclude infection.
• Acetaminophen pattern: aminotransferases in the tens of thousands with a relatively low bilirubin; ischemic hepatitis looks similar but has a sharp rise-and-fall with disproportionate LDH elevation.